83,888 Shares in Aurinia Pharmaceuticals Inc $AUPH Purchased by Man Group plc

Man Group plc purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the second quarter, Holdings Channel reports. The firm purchased 83,888 shares of the biotechnology company’s stock, valued at approximately $1,424,000.

Other institutional investors also recently bought and sold shares of the company. Cvfg LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $1,000,000. Ritholtz Wealth Management grew its stake in Aurinia Pharmaceuticals by 21.5% in the 1st quarter. Ritholtz Wealth Management now owns 314,426 shares of the biotechnology company’s stock valued at $4,660,000 after acquiring an additional 55,610 shares during the period. Renaissance Technologies LLC increased its holdings in Aurinia Pharmaceuticals by 4.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock worth $24,658,000 after acquiring an additional 73,700 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Aurinia Pharmaceuticals in the 1st quarter worth $1,340,000. Finally, Rice Hall James & Associates LLC acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $7,070,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on AUPH. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Aurinia Pharmaceuticals Stock Up 1.5%

NASDAQ AUPH opened at $16.29 on Thursday. The business has a fifty day moving average price of $15.87 and a 200 day moving average price of $15.53. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. The company has a market cap of $2.17 billion, a P/E ratio of 7.11 and a beta of 1.40. Aurinia Pharmaceuticals Inc has a one year low of $10.34 and a one year high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The company had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. Research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.